Main Menu
12
Jan
2018

The ICR responds to the FDA approval of olaparib for women with BRCA-mutant​​ advanced breast cancer

Metastatic breast cancer cells in pleural fluid

Metastatic breast cancer cells in pleural fluid. Image by Ed Thuman. CC license BY 2.0

The Institute of Cancer Research, London, strongly welcomes the news that olaparib (trade name Lynparza) has been approved by the US Food and Drug Administration (FDA) for patients with advanced breast cancer. 

Science carried out at The Institute of Cancer Research (ICR) underpinned the development of PARP inhibitors such as olaparib for women with BRCA-mutant breast and ovarian cancer. 

Professor Andrew Tutt, Director of the Breast Cancer Now Research Centre at The Institute of Cancer Research, was part of the early laboratory research behind PARP inhibitors in patients with BRCA mutations, and led some of the early clinical trials of olaparib. He said:
 
“We are delighted that the FDA has approved olaparib for advanced breast cancer in women who have inherited BRCA1 or BRCA2 mutations. This is excellent news for women with this uncommon but important genetic form of breast cancer many of whom took part in the clinical trials.
 
“The first steps in this journey were made in Alan Ashworth’s lab at the ICR, funded by Breast Cancer Now and Cancer Research UK. The discoveries made then drove the development of clinical trials in breast cancer, both at the ICR and The Royal Marsden NHS Foundation Trust, and with our many international genetic oncology colleagues.”

The ICR's Division of Breast Cancer Research contains over 100 scientists and clinicians. A key priority for the division is to identify and characterise breast cancer susceptibility genes

Find out more

'A perfect example'

Professor Chris Lord, Deputy Director of the Breast Cancer Now Research Centre, at the ICR, said:
 
“This drug is a perfect example of how understanding a patient’s genetics and the biology of their tumour can be used to target its weaknesses and personalise treatment. Olaparib will now provide thousands of women in the US with a treatment that acts directly against their inherited genetic mutation.
 
“We are very proud to have discovered the genetically selected indication for olaparib and played a role in the clinical development of the drug, and now eagerly await decisions by the European Medicines Agency, and ultimately NICE, which we hope will make olaparib available to women with BRCA mutant breast cancer in the UK as soon as possible.”

Tags

breast cancer BRCA olaparib andrew tutt NICE European Medicines Agency statement
comments powered by Disqus
We use cookies to ensure that we give you the best experience on our website. By continuing to use this website, you are agreeing to our use of cookies on your device as described in our cookie policy. You can change your cookie settings at any time but parts of our site will not function correctly without them.